Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | -1.49% | 176.12 | 0.7% | $1154.91m | |
| LLY | Eli Lilly & Co. | -0.17% | 368.68 | 1.1% | $1075.50m | |
| MRK | Merck & Co., Inc. | -0.98% | 108.93 | 0.7% | $992.38m | |
| PFE | Pfizer Inc. | -2.01% | 49.71 | 0.9% | $934.38m | |
| ABBV | AbbVie, Inc. | -0.11% | 163.76 | 1.9% | $884.04m | |
| BMY | Bristol-Myers Squibb Co. | -0.98% | 79.91 | 1.1% | $741.36m | |
| AZN | AstraZeneca Plc | 0.21% | 68.56 | 1.0% | $355.43m | |
| HZNP | Horizon Therapeutics Plc | -1.66% | 96.85 | 5.4% | $295.13m | |
| GSK | GSK Plc | 7.85% | 37.92 | 0.3% | $247.06m | |
| IDXX | IDEXX Laboratories, Inc. | -1.64% | 415.39 | 3.9% | $191.92m | |
| NVS | Novartis AG | -0.25% | 90.73 | 0.2% | $185.59m | |
| CTLT | Catalent, Inc. | -5.00% | 48.23 | 1.9% | $175.42m | |
| ALNY | Alnylam Pharmaceuticals, Inc. | -2.90% | 219.64 | 8.0% | $156.22m | |
| NVO | Novo Nordisk A/S | -1.03% | 125.77 | 0.1% | $154.68m | |
| SNY | Sanofi | 8.06% | 48.55 | 0.2% | $133.18m |
Company Profile
MyMD Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which engages in the development of drug products targeting aging, age-related, and autoimmune diseases, chronic pain, anxiety, and sleep disorders. It focuses on developing and commercializing the MyMD-1 and SUPERA-CBD therapeutic platforms. MyMD-1 is a clinical stage small molecule that regulates the immunometabolic system to treat autoimmune diseases. Supera-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in Baltimore, MD.